In This Article:
AbbVie (ABBV), a large drug maker, is jumping 8% after the company provided significantly higher-than-expected 2025 earnings per share guidance this morning. Additionally, the company's Q4 revenue came in above analysts' average estimate. A Look at AbbVie's Guidance and Results ABBV provided 2025 EPS guidance, excluding certain items, of $12.12 to $12.32. Analysts' average estimate heading into the print was just $10.39.
A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. Also noteworthy is that the firm raised its 2027 outlook for the combined sales of its Skyrizi and Rinvoq drugs to "more than $31 billion," versus "more than $27 billion" previously. "This guidance assumes Skyrizi revenues of more than $20 billion and Rinvoq revenues of more than $11 billion in 2027," ABBV reported. Skyrizi is used to treat a variety of inflammatory conditions, including psoriasis and Crohn's. Also an anti-inflammatory treatment, Rinvoq combats rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ulcerative colitis. ABBV reported overall Q4 sales of $15.1 billion, versus analysts' average estimate of $14.83 billion. Its sales climbed 5.6% versus the same period a year earlier. However, it generated Q4 EPS, excluding certain items, of $2.16, below analysts' mean outlook of $2.26. In Q4 of 2023, it generated adjusted EPS of $2.79. The Recent Price Action of ABBV Stock In the last month, the shares have risen 4%, while they are down 7% in the last three months. While we acknowledge the potential of ABBV, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ ALSO 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock Disclosure: None. This article is originally published at Insider Monkey.